Avalo Therapeutics Inc. AVTX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized mon…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees33
TickerAVTX
Statistics
Market Cap$380.2M
Revenue (TTM)$59000
Net Income-$78.3M
Net Margin-132642.4%
EPS$-5.84
P/E2.30
P/S12179.18
P/B4.93
EV/EBITDA-8.07
ROE-88.8%
Dividend Yield—
Price$15.43
Data: Twelve Data · Revenue = mcap / P/S